Short Interest in Dermata Therapeutics, Inc. (NASDAQ:DRMA) Drops By 23.8%

Dermata Therapeutics, Inc. (NASDAQ:DRMA) was the recipient of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 188,800 shares, a decrease of 23.8% from the February 28th total of 247,700 shares. Approximately 4.7% of the company’s stock are short sold. Based on an average daily trading volume, of 349,300 shares, the short-interest ratio is currently 0.5 days.

Dermata Therapeutics Stock Down 1.9 %

DRMA stock traded down $0.02 during trading hours on Tuesday, hitting $1.06. The company’s stock had a trading volume of 54,243 shares, compared to its average volume of 1,133,290. Dermata Therapeutics has a 12 month low of $1.00 and a 12 month high of $6.67. The stock has a 50 day moving average price of $1.20 and a two-hundred day moving average price of $1.30. The company has a market capitalization of $5.76 million, a PE ratio of -0.07 and a beta of 0.65.

About Dermata Therapeutics

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.